Were any of Anderson Woodrow D’s Indivior (INDV) share disposals open-market sales?

The reported disposals were not open-market sales. They were tax-withholding dispositions, where 8,283 and 2,682 common shares were used to satisfy tax obligations associated with the vesting of performance and restricted stock units on March 3, 2026.

What price was used for the Indivior (INDV) tax-withholding share dispositions?

The tax-withholding dispositions of Indivior common stock were reported at a transaction price of $31.98 per share. These transactions were coded as “F,” indicating shares delivered to cover tax liabilities arising from the vesting of stock-based awards on March 3, 2026.

Indivior (INDV) CAO reports stock unit vesting and tax-withholding share disposals

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. Chief Accounting Officer Anderson Woodrow D reported equity award vesting and related share movements on March 3, 2026. Performance stock units granted on March 3, 2023 vested at 76.6%, resulting in 18,364 common shares out of a 23,975 target amount, and restricted stock units also vested.

To cover tax withholding tied to these vestings, 8,283 and 2,682 common shares were disposed of at $31.98 per share through tax-withholding transactions, rather than open-market sales. After these derivative conversions and tax withholdings, the reporting person held 24,638 shares of common stock directly.

Insider Trade Summary

29,921 shares exercised/converted

Mixed 6 txns

Insider Anderson Woodrow D

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise	Performance Stock Units	23,975	$0.00	--
Exercise	Restricted Stock Units	5,946	$0.00	--
Exercise	Common Stock	18,364	$0.00	--
Tax Withholding	Common Stock	8,283	$31.98	$265K
Exercise	Common Stock	5,946	$0.00	--
Tax Withholding	Common Stock	2,682	$31.98	$86K

Holdings After Transaction: Performance Stock Units — 0 shares (Direct); Restricted Stock Units — 0 shares (Direct); Common Stock — 29,657 shares (Direct)

Footnotes (1)

Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 18,364 shares vested out of the 23,975 target amount. Each performance stock unit and restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Shares used to satisfy tax withholding obligations associated with the vesting of performance stock units on March 3, 2026. Shares used to satisfy tax withholding obligations associated with the vesting of restricted stock units on March 3, 2026. This award is fully vested in accordance with its terms, effective March 3, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/05/2026 - 04:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderson Woodrow D

(Last)

(First)

(Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD

23235

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2026		M		18,364⁽¹⁾	A	⁽²⁾	29,657	D
Common Stock	03/03/2026		F		8,283⁽³⁾	D	$31.98	21,374	D
Common Stock	03/03/2026		M		5,946	A	⁽²⁾	27,320	D
Common Stock	03/03/2026		F		2,682⁽⁴⁾	D	$31.98	24,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Stock Units	$0⁽²⁾	03/03/2026		M			23,975	03/03/2026⁽¹⁾	⁽¹⁾	Common Stock	23,975	⁽²⁾	0	D
Restricted Stock Units	$0⁽²⁾	03/03/2026		M			5,946	03/03/2026⁽⁵⁾	⁽⁵⁾	Common Stock	5,946	⁽²⁾	0	D

Explanation of Responses:

1. Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 18,364 shares vested out of the 23,975 target amount.

2. Each performance stock unit and restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. Shares used to satisfy tax withholding obligations associated with the vesting of performance stock units on March 3, 2026.

4. Shares used to satisfy tax withholding obligations associated with the vesting of restricted stock units on March 3, 2026.

5. This award is fully vested in accordance with its terms, effective March 3, 2026.

Remarks:

	/s/Alice Givens, Power of Attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Indivior (INDV) report for Anderson Woodrow D?

Indivior reported that Chief Accounting Officer Anderson Woodrow D had performance stock units and restricted stock units vest into common stock on March 3, 2026, along with related share dispositions solely to satisfy tax withholding obligations tied to those vestings.

How many Indivior (INDV) performance stock units vested for Anderson Woodrow D?

Performance stock units granted on March 3, 2023 vested at 76.6%, so 18,364 common shares vested out of a 23,975 target amount. Each performance stock unit represented a contingent right to receive one share of Indivior’s common stock when the performance conditions were met.

How many Indivior (INDV) shares did Anderson Woodrow D hold after these transactions?

Following the derivative exercises, conversions, and tax-withholding share dispositions on March 3, 2026, Anderson Woodrow D was reported to directly own 24,638 shares of Indivior Pharmaceuticals, Inc. common stock, reflecting his updated post-vesting equity position.

What do Indivior (INDV) performance and restricted stock units represent for Anderson Woodrow D?

Each performance stock unit and restricted stock unit granted to Anderson Woodrow D represents a contingent right to receive one share of Indivior’s common stock, which converts into actual shares when the specified performance or vesting conditions are satisfied under the award terms.